A detailed history of Squarepoint Ops LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 135,500 shares of LYEL stock, worth $82,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares
135,500
Holding current value
$82,655
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $1.88 $153,115 - $254,740
135,500 New
135,500 $186,000
Q1 2024

May 15, 2024

SELL
$1.71 - $3.07 $395,133 - $709,391
-231,072 Reduced 75.82%
73,704 $164,000
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.35 $423,638 - $716,223
304,776 New
304,776 $591,000
Q3 2021

Nov 15, 2021

SELL
$11.0 - $17.95 $560,857 - $915,216
-50,987 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$15.99 - $16.89 $815,282 - $861,170
50,987 New
50,987 $828,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.